Drug Database
CL

clindamycin (ResiDerm A / Zindaclin)

✓ Approved

Teva Pharmaceutical Industries Ltd. · Small Molecule · Small Molecule

What is clindamycin?

clindamycin is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesResiDerm A, Zindaclin
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Therapeutic Indications

clindamycin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersAcne✓ Approved

Related Research Articles

PubMedFrontiers in veterinary science2026-10-22

Antimicrobial resistance profiling of Streptococcus suis isolated from neurological cases in Chilean pigs.

Larenas-Muñoz Fernanda F, Videla-Martínez Francisca F, Ruiz-Garrido Álvaro Á

Streptococcus suis is an important swine pathogen and an emerging zoonotic bacterium, with multidrug-resistant (MDR) strains representing an increasing concern for both animal and public health. This report describes the pathological findings and antimicrobial susceptibility profiles of MDR S. suis isolates recovered from the central nervous system of two pigs from a commercial swine farm in south-central Chile. Brain and spinal cord samples were examined by histopathology and microbiological culture, followed by bacterial identification and antimicrobial susceptibility testing using an antibiogram and minimum inhibitory concentration (MIC) analysis. Histopathological examination revealed non-suppurative inflammatory lesions characterized by mononuclear perivascular cuffing, consistent with meningoencephalomyelitis and myelitis. S. suis was isolated from the brain and/or spinal cord of both pigs. MIC testing demonstrated resistance to spectinomycin, ampicillin/amoxicillin, ceftiofur, penicillin, florfenicol, enrofloxacin, clindamycin, tilmicosin, tulathromycin, tylosin tartrate, tiamulin, sulfadimethoxine, trimethoprim/sulfamethoxazole, oxytetracycline, and chlortetracycline, indicating an MDR phenotype. Both isolates remained susceptible to gentamicin, while variable susceptibility was observed for danofloxacin, neomycin, tulathromycin, tiamulin, and trimethoprim/sulfamethoxazole. To the authors' knowledge, this is the first report of MDR S. suis associated with neurological disease in pigs from Chile. These findings provide additional information on the antimicrobial susceptibility of S. suis in Chile and support the need for broader antimicrobial resistance surveillance under a One Health framework, as well as the prudent use of antimicrobials in swine production.

PMID 42903082
Read full article →
PubMedJournal of the American Academy of Dermatology2026-10-20

Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa.

Naik Haley B HB, Yeung Howa H, Frazer-Green Lindsy L, Daveluy Steven Daniel SD et al.

Hidradenitis suppurativa affects 0.7% to 1.5% of the global population and causes substantial disability and meaningfully impairs quality of life. To provide evidence-based recommendations for the management of hidradenitis suppurativa. A workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach to assess the certainty of evidence and to develop recommendations. This guideline presents 37 evidence-based recommendations. Strong recommendations are made for adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Conditional recommendations are made for topical clindamycin, resorcinol, and ruxolitinib; oral doxycycline, tetracycline, and clindamycin with rifampin; intravenous ertapenem; spironolactone; short-term systemic corticosteroids; upadacitinib; specific procedural interventions; tobacco cessation; supportive pain management; and zinc supplementation and vitamin D repletion. Analysis is limited to best evidence available from systematic review. These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa.

PMID 42900024
Read full article →
PubMedInfection2026-10-20

Increasing contribution of dental antibiotic prescribing to community-acquired Clostridioides difficile infection: a 9-year retrospective cohort study.

Miklaušić Pavić Božana B, Begovac Josip J, Pristaš Irina I, Skuhala Tomislava T

Community-acquired Clostridioides difficile infection (CA-CDI) is increasingly recognized outside healthcare settings, yet the contribution of dental antibiotic prescribing remains poorly characterized. This study compared patients with CA-CDI following antibiotics prescribed by dental practitioners versus family physicians. We conducted a retrospective cohort study at the University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia, including adults with a first episode of confirmed CA-CDI following outpatient antibiotic exposure between 2011 and 2019. Characteristics were compared by prescriber. Among 666 patients with CA-CDI, 190 (28.5%) had received antibiotics from dental practitioners and 476 (71.5%) from family physicians. Dental-associated CA-CDI increased significantly over time (13.1% in 2011 to 31.1% in 2019; p = 0.003). Dental patients had a lower comorbidity burden, with less frequent diabetes, chronic obstructive pulmonary disease, and proton pump inhibitor use. Amoxicillin-clavulanate was the most frequently prescribed antibiotic overall; clindamycin was more common among dental patients (39.9% vs. 11.9%), 79.7% of whom had no penicillin allergy. Severity and treatment duration were similar between groups. Dental antibiotic prescribing emerged as an increasingly important contributor to CA-CDI, associated with higher clindamycin use despite a lower burden of traditional risk factors, highlighting the need to strengthen antimicrobial stewardship in dental practice.

PMID 42900457
Read full article →
PubMedJournal of the European Academy of Dermatology and Venereology : JEADV2026-10-20

Hidradenitis suppurativa skin microbiome: In-depth analysis and modulation by systemic therapies.

Amar Yacine Y, Baumann Diana D, Niedermeier Sebastian S, Silva Rafaela L RL et al.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a multifactorial pathogenesis involving genetic, lifestyle and microbial factors. While cutaneous microbiome shifts have been reported for this disease, the impact of systemic immunomodulators and antibiotics on HS microbiome remains poorly defined. To characterize species-level cutaneous dysbiosis in HS and evaluate the effects of three standard-of-care systemic therapies, clindamycin/rifampicin (ATB), adalimumab (ADA) and secukinumab (SEC) on skin microbial composition. We performed 16S rRNA sequencing on 251 skin swabs from lesional and non-lesional sites of 52 HS patients and 31 healthy matched controls. In a sub-cohort of 28 patients, microbial shifts were evaluated following 12 weeks of therapy with ATB (n = 8), ADA (n = 12) and SEC (n = 8). HS skin exhibited profound dysbiosis defined by the depletion of homeostatic commensals (Cutibacterium acnes, Staphylococcus hominis, S. epidermidis) and a synergistic expansion of anaerobic pathogens, primarily Gram-positive anaerobic cocci (GPAC; Finegoldia magna, Peptoniphilus grossensis and Fenollaria massiliensis), Lawsonella clevelandensis and Campylobacter ureolyticus. A 13-taxa microbial signature accurately discriminated the HS phenotype (AUC = 0.92). Following 12 weeks of treatment, ATB markedly attenuated dysbiosis by reducing pathogen loads and significantly increasing microbial richness. In contrast, ADA and SEC did not alter pathogen abundance and were associated with a slight decline in protective commensals. Systemic antibiotics partially restore cutaneous microbiome homeostasis in HS by targeting anaerobic pathogens while preserving beneficial commensals, an effect not observed with the tested biologics. These findings highlight the need for microbiome-directed adjuvant therapies to complement immunomodulation in HS management.

PMID 42899700
Read full article →
PubMedInternational journal of pharmaceutics2026-10-19

Development of stereolithography 3D printed hollow vaginal devices with pore modulation to tailor the drug release.

Lakkala Preethi P, Munnangi Siva Ram SR, Narala Nagarjuna N, Wang Honghe H et al.

Vaginal infections affect nearly 70% of women worldwide at least once in their lifetime, yet conventional therapies remain suboptimal due to short residence time, leakage, and poor patient adherence. Long-acting vaginal systems such as rings and inserts can prolong drug release but are often limited by formulation constraints and the inability to accommodate diverse therapeutic agents. To address these challenges, we developed a novel hollow vaginal device fabricated via stereolithography (SLA) 3D printing using a biocompatible elastic resin. The C-shaped device features two precisely engineered pore openings that enable controlled drug release. Devices with pore diameters ranging from 0.5-2.0 mm were fabricated and loaded with a clindamycin phosphate aqueous gel, a first-line therapy for bacterial vaginosis. Drug release was modulated by the pore diameter and, at a fixed pore diameter, by the gel viscosity, enabling the dose to be adjusted. Mechanical testing confirmed that the elastic structure withstands repeated compression without deformation, ensuring mechanical robustness during vaginal retention. This versatile and customizable platform enables controlled and sustained intravaginal delivery of a wide range of therapeutics, representing a significant step toward patient-centric, next-generation vaginal drug delivery systems.

PMID 42896664
Read full article →
PubMedJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2026-10-16

Post-COVID-19 changes in the epidemiology of group A Streptococcus infections in Taiwan: A retrospective study.

Goh Wai-Ki WK, Liu Yun-Chung YC, Hu Ya-Li YL, Ho Shu-Yuan SY et al.

Temporal changes in group A Streptococcus (GAS) infections have been reported worldwide, but long-term data from Taiwan remain limited. This study evaluated temporal patterns, age-specific disease characteristics, antimicrobial susceptibility, and factors associated with invasive GAS infection. We conducted a retrospective study that included patients with GAS infection at a tertiary referral center in Taiwan from 2015 to 2024. Monthly hospital-identified case counts were described, and multivariable logistic regression was used to identify factors associated with invasive disease. Among 454 patients, 33 (7.3%) had invasive disease. Monthly case counts declined markedly during the COVID-19 period (2020-2022), remained low in 2023, and increased to 45 cases in 2024, still below pre-pandemic annual levels. Adults aged ≥65 years accounted for 14 of 33 invasive cases (42.4%). Age ≥18 years (adjusted odds ratio [aOR], 11.6; 95% confidence interval [CI], 4.4-30.9; p < 0.001) and the presence of two or more underlying disease categories (aOR, 29.7; 95% CI, 10.4-84.5; p < 0.001) were associated with invasive disease. All isolates were susceptible to penicillin. Invasive isolates showed higher susceptibility to clindamycin and erythromycin but lower susceptibility to tetracycline than noninvasive isolates. Hospital-identified GAS cases showed substantial temporal variation. Older age and greater underlying disease burden were associated with invasive infection. These findings may support clinical risk assessment and institutional surveillance.

PMID 42888059
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about clindamycin